Thubrikar Aortic Valve completes initial CE Mark-enabling TAVI-1 Study
NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., announced today that it has completed the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis. The implantations were performed by the Principal Investigator Jaroslaw Trebacz, M.D., at the Specialty Hospital Jana Pawla II, Krakow, Poland. The 5-patient study was … [Read more…]
